Patent · US Active

Triazolopyrazine

US11077107B2 · kind B2 · utility

0Cited by

7References

66Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Harald Engelhardt · Ebreichsdorf, AT
Davide Gianni · Wien, AT
Christian Alan Paul Smethurst · Wien, AT

Key dates

Filing date	Apr 19, 2019
Grant date	Aug 3, 2021
Priority date	—
Expiry date	Apr 19, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compounds of the formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.